METHODS: This is a single-center observational retrospective study on EE-DCR via a posterior approach. Resolution of epiphora and dacryocystitis were analyzed after 1 (T1) and 6-months (T2) from surgery. Surgical success was defined as anatomical (patency at irrigation, no recurring dacryocystitis) or complete (zeroing of Munk score).
RESULTS: Twenty patients (32 sides) were enrolled. Preoperatively, 93.75% (n = 30/32) presented severe (Munk 3-4) epiphora and 68.75% (n = 22/32) recurrent dacryocystitis. At T1, 50.0% (n = 16/32) were referred with residual epiphora (Munk ≥ 1) and 18.75% (n = 6/32) dacryocystitis. At T2, 31.25% (n = 10/32) still complained of epiphora (Munk ≥ 1) and 6.25% (n = 2/32) dacryocystitis. Difference of outcomes at aggregate and paired timepoints (except for T1 versus T2) resulted in statistical significance (p < 0.05). At T2, 22 (68.75%) complete, 8 (25.0%) anatomical successes and 2 (6.25%) surgical failures were observed.
CONCLUSIONS: Despite the chronic uptake of anti-glaucoma eye drops, EE-DCR guaranteed high rates of clinical relief from epiphora and remarkable decreases in the rates of recurrent dacryocystitis.
方法:这是一项通过后路对EE-DCR进行的单中心观察性回顾性研究。手术后1(T1)和6个月(T2)分析了泪液和泪囊炎的消退。手术成功被定义为解剖学(冲洗时通畅,无复发性泪囊炎)或完全(Munk评分归零)。
结果:纳入20例患者(32侧)。术前,93.75%(n=30/32)出现严重(Munk3-4)上泪液和68.75%(n=22/32)复发性泪囊炎。在T1时,50.0%(n=16/32)被转诊为残留的泪囊炎(Munk≥1)和18.75%(n=6/32)。在T2时,仍有31.25%(n=10/32)的泪滴(Munk≥1)和6.25%(n=2/32)的泪囊炎。在总时间点和配对时间点(除了T1与T2)的结果差异导致统计学意义(p<0.05)。在T2,22(68.75%)完成,观察到8例(25.0%)解剖成功和2例(6.25%)手术失败。
结论:尽管抗青光眼滴眼液长期服用,EE-DCR保证了泪溢的高临床缓解率,并显着降低了泪囊炎的复发率。